These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 4214664)

  • 1. Long-term effect of halofenate on serum lipids.
    Aronow WS; Vangrow J; Pagano J; Khemka M; Vawter M; Papageorge's NP
    Curr Ther Res Clin Exp; 1974 Sep; 16(9):897-903. PubMed ID: 4214664
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term efficacy of halofenate on serum triglyceride levels.
    Aronow WS; Vicario MD; Moorthy K; King J; Vawter M; Papageorge's NP
    Curr Ther Res Clin Exp; 1975 Dec; 18(6):855-61. PubMed ID: 813950
    [No Abstract]   [Full Text] [Related]  

  • 3. Halofenate: an effective hypolipemia- and hypouricemia-inducing drug.
    Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
    Curr Ther Res Clin Exp; 1973 Dec; 15(12):902-6. PubMed ID: 4203573
    [No Abstract]   [Full Text] [Related]  

  • 4. The metabolic spectrum of halofenate.
    Ryan JR
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):239-43. PubMed ID: 51838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
    Wolfram G; Keller C; Kilani C; Zöllner N
    Verh Dtsch Ges Inn Med; 1973; 79():1291-3. PubMed ID: 4597609
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
    Bassett DR; Mikkelsen WM; Buckingham RB; Block WD; Sidiq M; Shakibai A; DiGaetano R; Liou LL
    Clin Pharmacol Ther; 1977 Sep; 22(3):340-51. PubMed ID: 330079
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
    Keller C; Wolfram G; Zöllner N
    Arzneimittelforschung; 1976; 26(12):2221-4. PubMed ID: 798591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uric acid level, coronary heart disease and serum lipids.
    Ciświcka-Sznajderman M; Ignatowska-Switalska H; Sznajderman M
    Pol Med J; 1972; 11(2):233-7. PubMed ID: 5071511
    [No Abstract]   [Full Text] [Related]  

  • 9. Halofenate, serum lipids, and exercise performance in coronary heart disease.
    Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
    Clin Pharmacol Ther; 1974 Jan; 15(1):67-72. PubMed ID: 4587107
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
    Krut LH; Seftel HC; Joffe BI
    S Afr Med J; 1977 Mar; 51(11):348-52. PubMed ID: 323994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of halofenate on serum lipids.
    Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP; Mays J
    Clin Pharmacol Ther; 1973; 14(3):358-65. PubMed ID: 4572798
    [No Abstract]   [Full Text] [Related]  

  • 12. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
    Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of hypoglycemic effect of sulfonylureas by halofenate.
    Jain AK; Ryan JR; McMahon FG
    N Engl J Med; 1975 Dec; 293(25):1283-6. PubMed ID: 171574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)].
    Kuntzen O; Hehl FJ; Walter E; Zimmermann R
    Arzneimittelforschung; 1978; 28(12):2349-52. PubMed ID: 227420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of halofenate on serum uric acid.
    Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP
    Clin Pharmacol Ther; 1973; 14(3):371-3. PubMed ID: 4572799
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
    Lisch HJ; Patsch J; Sailer S; Braunsteiner H
    Atherosclerosis; 1975; 21(3):391-9. PubMed ID: 1148032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum uric-acid and serum lipids. Statistical correlations. Report of 1 000 cases (author's transl)].
    Bouvenot G; Bartolin R; Sciara M; Delboy C; Arnaud C
    Sem Hop; 1980 Feb 8-15; 56(5-6):263-4. PubMed ID: 6243798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia.
    Feldman EB; Gluck FB; Carter AC
    J Clin Pharmacol; 1978; 18(5-6):241-8. PubMed ID: 346616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
    Hutchison JC; Wilkinson WH
    Atherosclerosis; 1973; 18(3):353-62. PubMed ID: 4584481
    [No Abstract]   [Full Text] [Related]  

  • 20. [The effect of ethyl-chlorophenoxyisobutyrate on the serum lipids in coronary sclerosis].
    Keller L; Rétsági G; Sebestyén M; Diczendy S; Erdélyi G
    Z Gesamte Inn Med; 1966 Mar; 21(6):169-72. PubMed ID: 5988081
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.